Autoantibody-positive healthy individuals with lower lupus risk display a unique immune endotype
Slight-Webb, S., Smith, M., Bylinska, A.
Background: Autoimmune diseases comprise a spectrum of illnesses and are on the rise worldwide. Although antinuclear antibodies (ANAs) are detected in many autoimmune diseases, up to 20% of healthy women are ANA-positive (ANA+) and most will never develop clinical symptoms. Furthermore, disease transition is higher among ANA+ African Americans compared with ANA+ European Americans.
Objective: We sought to determine the immune features that might define and prevent transition to clinical autoimmunity in ANA+ healthy individuals.
Methods: We comprehensively phenotyped immune profiles of African Americans and European Americans who are ANA-negative (ANA-) healthy, ANA+ healthy, or have SLE using single cell mass cytometry, next-generation RNA-sequencing, multiplex cytokine profiling, and phospho-signaling analyses.
Results: We found that, compared with both ANA- and ANA+ healthy individuals, patients with SLE of both races displayed T-cell expansion and elevated expression of type I and II interferon pathways. We discovered a unique immune signature that suggests a suppressive immune phenotype and reduced CD11C+ autoimmunity-associated B cells in healthy ANA+ European Americans that is absent in their SLE or even healthy ANA- counterparts, or among African American cohorts. In contrast, ANA+ healthy African Americans exhibited elevated expression of T-cell activation markers and higher plasma levels of IL-6 than did healthy ANA+ European Americans.
Conclusions: We propose that this novel immune signature identified in ANA+ healthy European Americans may protect them from T-cell expansion, heightened activation of interferon pathways, and disease transition.
Keywords: ANA+ healthy; Autoantibodies; SLE; T cells; cytokines; immune suppression; race.
Slight-Webb, S., Smith, M., Bylinska, A. "Autoantibody-positive healthy individuals with lower lupus risk display a unique immune endotype" Journal of Allergy and Clinical Immunology (2021): DOI: 10.1016/j.jaci.2020.04.047